Coinbase Founder’s Longevity Startup Triples in Value
RSS SUMMARY · AGGREGATED FROM TWSJ
Now worth $3.1 billion, NewLimit plans to test its RNA therapy in alcohol-related liver-disease patients next year
Now worth $3.1 billion, NewLimit plans to test its RNA therapy in alcohol-related liver-disease patients next year
Now worth $3.1 billion, NewLimit plans to test its RNA therapy in alcohol-related liver-disease patients next year
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
Business
UAW Strike Takes ‘Strategic’ Aim at Some of GM’s Most Profitable Vehicles
TWSJ·2h ago·3 min read
Business
Pride Groups Plan for a Future Without Some of Their Biggest Corporate Sponsors
TWSJ·1h ago·3 min read
Business
BOE’s Greene Says Case for Rise in Key Interest Rate is Growing
TWSJ·1h ago·3 min read
Business
Auto & Transport Roundup: Market Talk
TWSJ·1h ago·3 min read
Related
On this beat
Business
Most Business Owners Are Leaving Money on the Table. This Bar Expert Figured Out Why.
ENTREPRENEUR·1h ago·3 min read
Business
New Survey Says AI Is Falling Woefully Short on One Big Promise — It ‘Should Be Making Executives Uncomfortable’
ENTREPRENEUR·5h ago·3 min read
Business
Nvidia CEO Declares That PCs Are About to Get Their First ‘Reinvention’ in 40 Years — Here’s What’s Changing
ENTREPRENEUR·4h ago·3 min read
Business
Morgan Stanley resets Monster stock price target after earnings
THE STREET·58m ago·3 min read